Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 2 , Pages 61-75 , June 2010

Oncologic photodynamic therapy photosensitizers: A clinical review

  • Ron R. Allison, MD

      Affiliations

    • 21st Century Oncology, Greenville, NC, 27834-3764, USA
    • ,
  • Claudio H. Sibata, PhD

      Affiliations

    • 21st Century Oncology, Greenville, NC, 27834-3764, USA
    • The Brody School of Medicine, Department of Radiation Medicine, East Carolina University, Leo W. Jenkins Cancer Center, Greenville, NC, 27858-4354, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 252 744 2900; fax: +1 252 744 3780.

References 

  1. Hausmann W. The photodynamic action of plant extracts containing chlorophyll. Biochem Z. 1907;12:331–334
  2. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine photodynamic therapy. Chem Soc Rev. 1995;24:19–33
  3. Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem. 2008;8(3):280–291
  4. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: An Historical Review. Photodiag Photodyn Ther. 2004;1(4):263–277
  5. Finsen NF. Phototherapy. London: Arnold; 1901;
  6. Raab O. On the effect of fluorescent substances on infusoria (German). Z Biology. 1900;39:524
  7. Von Tappeiner H, Joldlbauer A. On the effect of photodynamic (fluorescent) substances on protozoa and enzymes. Arch Klin Med. 1904;80:427–487
  8. Jodlbauer A, Von Tappeiner H. On the participation of oxygen in the photodynamic effect of fluorescent substances. Münch Med Wochenschr. 1904;52:1139–1141
  9. Jesionek A, Von Tappeiner H. On the treatment of skin cancers with fluorescent substances. Arch Klin Med. 1905;82:223–227
  10. Dougherty TJ, Henderson BW, Schwartz S, Winkelman JW, Lipson RL. Historical Perspective. In:  Henderson BW,  Dougherty TJ editor. Photodynamic Therapy. New York: Marcel Dekker; 1992;p. 1–15
  11. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38(8):2628–2635
  12. Bonnett R. Photodynamic therapy in historical perspective. Rev. Contemp. Pharmacother. 1999;10:1–17
  13. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy: a new concept in medical treatment. Braz J Med Biol Res. 2000;33(8):869–880
  14. O’Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol. 2009;85(5):1053–1074
  15. Gorman A, Killoran J, O'Shea C, Kenna T, Gallagher WM, O'Shea DF. In vitro demonstration of the heavy-atom effect for photodynamic therapy. J Am Chem Soc. 2004;126(34):10619–10631
  16. Allison RR, Mang TS, Wilson BD. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cutan Med Surg. 1998;17(2):153–163
  17. Mang T. Lasers and light sources for PDT: past, present and future. Photodiag Photodyn Ther. 2004;1(1):43–48
  18. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiag Photodyn Ther. 2004;1(4):279–293
  19. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2009;24(2):259–268
  20. Bisland SK, Lilge L, Lin A, Rusnov R, Wilson BC. Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol. 2004;80:22–30
  21. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008;53(9):R61–109
  22. Allison RR, Mota HC, Bagnato VS, Sibata CH. Bio-nanotechnology and photodynamic therapy--state of the art review. Photodiagnosis Photodyn Ther. 2008;5(1):19–28
  23. Pandey RK, Herman CK. Shedding some light on tumors. Chem Ind. 1998;21:739–743
  24. Sternberg ED, Dolphin D. Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron. 1998;54(17):4151–4202
  25. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889–905
  26. Berry RJ. “Small clones” in irradiated tumour cells in vivo. Kinetics of re-growth of murine leukaemia cells surviving irradiation with x-rays, fast neutrons and accelerated charged particles. Br J Radiol. 1967;40(472):285–291
  27. Clapp P, Charyulu KK, Tayao MS, Tyree EB, Nickson JJ, Lawrence W. Regional Oxygenation and Therapeutic Response to Irradiation; an Experimental Study. Cancer. 1965;18:927–936
  28. Moser JG. 2nd and 3nd Generation Photosensitizers. Amsterdam: Harwood academic publishers; 1998;
  29. Peng Q, Farrants GW, Madslien K, Bommer JC, Moan J, Danielsen HE, et al. Subcellular localization, redistribution and photobleaching of sulfonated aluminum phthalocyanines in a human melanoma cell line. Int J Cancer. 1991;49(2):290–295
  30. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B. 2002;66(2):89–106
  31. Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol. 1992;55(1):145–157
  32. Prasad PN. Introduction to Biophotonics. Hoboken, NJ: John Wiley & Sons, Inc.; 2003;
  33. Valeur B. Molecular Fluorescence. Weinheim, FRG: John Wiley VCH; 2003;
  34. Kato H, Harada M, Ichinose S, Usuda J, Tsuchida T, Okunaka T. Photodynamic therapy (PDT) of lung cancer: experience of the Tokyo Medical University. Photodiagn Photodyn Ther. 2004;1(1):49–55
  35. Allison RR, Sibata CH. Photodiagnosis for cutaneous malignancy: a brief clinical and technical review. Photodiagnosis Photodyn Ther. 2008;5(4):247–250
  36. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5(8):497–508
  37. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother. 2001;2(6):917–927
  38. Patterson MS, Wilson BC. Photodynamic Therapy. In:  Dyh JV editors. The Modern Technology of Radiation Oncology. Madison: Medical Physics Publishing, Madison; 1999;p. 941–980
  39. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 1991;126(3):296–303
  40. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH. Photosensitizers in clinical PDT. Photodiag Photodyn Ther. 2004;1(1):27–42
  41. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci. 2007;6(12):1234–1245
  42. Scourides PA, Bohmer RM, Kaye AH, Morstyn G. Nature of the tumor-localizing components of hematoporphyrin derivative. Cancer Res. 1987;47(13):3439–3445
  43. Berg K, Moan J, Lysosomes . microtubules as targets for photochemotherapy of cancer. Photochem Photobiol. 1997;65(3):403–409
  44. Richter AM, Yip S, Meadows H, Jain AK, Neyndorff H, Moreno G, et al. Photosensitizing potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. J Clin Laser Med Surg. 1996;14(5):335–341
  45. Rosenkranz AA, Jans DA, Sobolev AS. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol Cell Biol. 2000;78(4):452–464
  46. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6(1–2):143–148
  47. Serebrovskaya O, Edelweiss EF, Stremovskiy O, Lukianov KA, Chudakov DM, Deyev SM. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. PNAS. 2009;106(23):9221–9225
  48. Fischer, H. and A. Stern, Die Chemie des Pyrrols. 1940 (reprinted by Johnson Reprint Corp., New York, 1968), Leipzig: Akademische Verlagsgesellschaft.
  49. Moss GB. Nomenclature of tetrapyrroles. Eur J Biochem. 1988;178(2):277–328
  50. Allison RR, Bagnato VS, Cuenca R, Downie GH, Sibata CH. The future of photodynamic therapy in oncology. Future Oncol. 2006;2(1):53–71
  51. Dougherty TJ. Photosensitization of malignant tumors. Semin Surg Oncol. 1986;2(1):24–37
  52. Dougherty TJ. Studies on the structure of porphyrins contained in Photofrin II. Photochem Photobiol. 1987;46:569–573
  53. Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. Prog Clin Biol Res. 1984;170:301–314
  54. Dougherty TJ. Photodynamic therapy. Photochem Photobiol. 1993;58(6):895–900
  55. Bernstein ZP, Wilson BD, Oseroff AR, Jones CM, Dozier SE, Brooks JS, et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. Aids. 1999;13(13):1697–1704
  56. Jones CM, Mang T, Cooper M, Wilson BD, Stoll HL. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol. 1992;27(6 Pt 1):979–982
  57. Taber SW, Fingar VH, Wieman TJ. Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. J Surg Oncol. 1998;68(4):209–214
  58. Allison R, Mang T, Hewson G, Snider W, Dougherty D. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer. 2001;91(1):1–8
  59. Moghissi K, Dixon K, Hudson E, Stringer M, Brown S. Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy. Thorax. 1997;52(3):281–283
  60. Kato H, Okunaka T, Konaka C. Photodynamic therapy for bronchogenic carcinoma. Nippon Geka Gakkai Zasshi. 1997;98(1):36–40
  61. Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc. 1997;72(7):595–602
  62. Savary JF, Grosjean P, Monnier P, Fontolliet C, Wagnieres G, Braichotte D, et al. Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. Endoscopy. 1998;30(3):258–265
  63. Grosjean P, Wagnieres G, Fontolliet C, van den Bergh H, Monnier P. Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514nm compared with 630nm light irradiation after sensitization with Photofrin II. Br J Cancer. 1998;77(11):1989–1995
  64. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS, Gerdes H, Overholt BF, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc. 1995;42(6):507–512
  65. Overholt BF, Panjehpour M. Photodynamic therapy in the management of Barrett's esophagus with dysplasia. J Gastrointest Surg. 2000;4(2):129–130
  66. Overholt BF, Panjehpour M. Photodynamic therapy in Barrett's esophagus. J Clin Laser Med Surg. 1996;14(5):245–249
  67. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49(1):1–7
  68. Biel MA. Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope. 1998;108(9):1259–1268
  69. Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B. 1996;36(2):157–168
  70. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol. 1995;11(5):346–354
  71. Popovic EA, Kaye AH, Hill JS. Photodynamic therapy of brain tumors. J Clin Laser Med Surg. 1996;14(5):251–261
  72. Eljamel MS. Brain photodiagnosis (PD), fluorescence guided resection (FGR) and photodynamic therapy (PDT): past, present and future. Photodiagnosis Photodyn Ther. 2008;5(1):29–35
  73. Nseyo UO, DeHaven J, Dougherty TJ, Potter WR, Merrill DL, Lundahl SL, et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg. 1998;16(1):61–68
  74. Allison RR, Zervos E, Sibata CH. Cholangiocarcinoma: an emerging indication for photodynamic therapy. Photodiagnosis Photodyn Ther. 2009;6(2):84–92
  75. Allison RR, Sibata CH. Photofrin photodynamic therapy: 2.0mg/kg or not 2.0mg/kg that is the question. Photodiagnosis Photodyn Ther. 2008;5(2):112–119
  76. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997;79(12):2282–2308
  77. Loh CS, MacRobert AJ, Bedwell J, Regula J, Krasner N, Bown SG. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br J Cancer. 1993;68(1):41–51
  78. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997;65(2):235–251
  79. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14(4):275–292
  80. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832–840
  81. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 2001;137(3):319–324
  82. MacCormack MA. Photodynamic therapy in dermatology: an update on applications and outcomes. Semin Cutan Med Surg. 2008;27(1):52–62
  83. Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: a review. Lasers Med Sci. 2009;in press
  84. Tierney E, Barker A, Ahdout J, Hanke CW, Moy RL, Kouba DJ. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009;35(5):725–746
  85. Tierney EP, Eide MJ, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther. 2008;10(2):81–86
  86. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid. Lancet. 1993;342(8864):147–148
  87. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer. 1996;78(7):1374–1383
  88. Gossner L, Sroka R, Hahn EG, Ell C. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Gastrointest Endosc. 1995;41(1):55–58
  89. Ackroyd R, Kelty CJ, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy. 2003;35(6):496–501
  90. Ortner MA, Zumbusch K, Liebetruth J, Ebert B, Fleige B, Dietel M, et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy. 2002;34(8):611–616
  91. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. Gut. 1995;36(1):67–75
  92. Messmann H, Mlkvy P, Buonaccorsi G, Davies CL, MacRobert AJ, Bown SG. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer. 1995;72(3):589–594
  93. Kriegmair M, Waidelich R, Baumgartner R, Lumper W, Ehsan A, Hofstetter A. Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?. Urologe A. 1994;33(4):276–280
  94. Waidelich R, Beyer W, Knuchel R, Stepp H, Baumgartner R, Schroder J, et al. Whole bladder PDT with 5-ALA and a white light source. Urology. 2003;61:332–337
  95. Zaak D, Sroka R, Khoder W, Adam C, Tritschler S, Karl A, et al. Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid—first clinical experiences. Urology. 2008;72(2):345–348
  96. Ca M. Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls. J Dermatolog Treat. 2003;14(Suppl 3):23–26
  97. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14(2):99–106
  98. Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48(2):227–232
  99. Sotiriou E, Koussidou T, Patsatsi A, Apalla Z, Ioannides D. 5-Aminolevulinic acid-photodynamic treatment for dermatophytic tinea pedis of interdigital type: a small clinical study. J Eur Acad Dermatol Venereol. 2009;23(2):203–204
  100. Sotiriou E, Panagiotidou D, Ioannides D. 5-Aminolevulininic acid photodynamic therapy treatment for tinea cruris caused by Trichophyton rubrum: report of 10 cases. J Eur Acad Dermatol Venereol. 2009;23(3):341–342
  101. Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, de Berker D, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22(11):1302–1311
  102. Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547–553
  103. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999;80(1–2):185–193
  104. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol. 2003;13(5):351–355
  105. Ray ER, Chatterton K, Khan MS, Chandra A, Thomas K, Dasgupta P, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 2009;in press
  106. Ray ER, Chatterton K, Khan MS, Thomas K, Chandra A, O’Brien TS. Hexylaminolaevulinate ‘blue light’ fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology. BJU Int. 2009;103(10):1363–1367
  107. Ray ER, Chatterton K, Thomas K, Khan MS, Chandra A, O’Brien TS. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. J Endourol. 2009;23(6):983–988
  108. Goldberg DJ. Photodynamic therapy in skin rejuvenation. Clin Dermatol. 2008;26(6):608–613
  109. Nestor MS, Gold MH, Kauvar AN, Taub AF, Geronemus RG, Ritvo EC, et al. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5(2):140–154
  110. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, et al. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res. 1997;57(18):4000–4007
  111. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, et al. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003;63(8):1806–1813
  112. Pandey RK, Bellnier DA, Smith KM, Dougherty TJ. Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem Photobiol. 1991;53(1):65–72
  113. Magne ML, Rodriguez CO, Autry SA, Edwards BF, Theon AP, Madewell BR. Photodynamic therapy of facial squamous cell carcinoma in cats using a new photosensitizer. Lasers Surg Med. 1997;20(2):202–209
  114. McCaw DL, Pope ER, Payne JT, West MK, Tompson RV, Tate D. Treatment of canine oral squamous cell carcinomas with photodynamic therapy. Br J Cancer. 2000;82(7):1297–1299
  115. Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy. Cancer Chemother Pharmacol. 2006;57(1):40–45
  116. Loewen GM, Pandey R, Bellnier D, Henderson B, Dougherty T. Endobronchial photodynamic therapy for lung cancer. Lasers Surg Med. 2006;38(5):364–370
  117. Ben-Hur E, Rosenthal I. The Phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;47(2):145–147
  118. Allen CM, Sharman WM, Van Lier JE. Current Status of phthalocyanines in the photodynamic therapy of cancer. J Porphyrins Phthalocyan. 2001;5:161–169
  119. van Leengoed HL, van der Veen N, Versteeg AA, van der Berg-Blok AE, Marijnissen JP, Star WM. Tumour tissue imaging using the localizing properties and fluorescence of some phthalocyanines. Int J Radiat Biol. 1991;60(1–2):121–124
  120. Peaston AE, Leach MW, Higgins RJ. Photodynamic therapy for nasal and aural squamous cell carcinoma in cats. J Am Vet Med Assoc. 1993;202(8):1261–1265
  121. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–387
  122. Lukyanets EA. Phthalocyanines as photosensitizers in the photodynamic therapy of cancer. J Porphyrins Phthalocyan. 1999;3(6–7):424–432
  123. Uspenskii LV, Chistov LV, Kogan EA, Loshchenov VB, Ablitsov Iu A, Rybin VK, et al. Endobronchial laser therapy in complex preoperative preparation of patients with lung diseases. Khirurgiia (Mosk). 2000;2:38–40
  124. Sokolov VV, Stranadko EF, Zharkova NN, Iakubovskaia RI, Filonenko EV, Astrakhankina TA. The photodynamic therapy of malignant tumors in basic sites with the preparations photohem and photosens (the results of 3 years of observations). Vopr Onkol. 1995;41(2):134–138
  125. Stranadko EF, Garbuzov MI, Zenger VG, Nasedkin AN, Markichev NA, Riabov MV, et al. Photodynamic therapy of recurrent and residual oropharyngeal and laryngeal tumors. Vestn Otorinolaringol. 2001;3:36–39
  126. Filonenko EV, Sokolov VV, Chissov VI, Lukyanets EA, Vorozhtsov GN. Photodynamic therapy of early esophageal cancer. Photodiagnosis Photodyn Ther. 2008;5(3):187–190
  127. Miller JD, Baron ED, Scull H, Hsia A, Berlin JC, McCormick T, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol. 2007;224(3):290–299
  128. Huang Z. An update on the regulatory status of PDT photosensitizers in China. Photodiagnosis Photodyn Ther. 2008;5(4):285–287
  129. Ben-Hur E, Kol R, Marko R, Riklis E, Rosenthal I. Combined action of phthalocyanine photosensitization and gamma-radiation on mammalian cells. Int J Radiat Biol. 1988;54(1):21–30
  130. Juzeniene A. Chlorin e6-based photosensitizers for photodynamic therapy and photodiagnosis. Photodiagnosis Photodyn Ther. 2009;6(2):94–96
  131. Talaporfin: LS 11, LS11, ME 2906, Mono-L-Aspartyl Chlorin e6, NP e6, NPE 6, Taporfin Sodium. Drugs in R&D, 2003;4(1):69–71.
  132. Saito K, Shibasaki S, Kurosawa T. The pharmacological action and pharmacokinetics of talaporfin sodium. Antibiotics Chemotherapy. 2004;20:1571–1576(in Japanese)
  133. Spikes JD. Chlorins as photosensitizers in biology and medicine. J Photochem Photobiol B. 1990;6(3):259–274
  134. Kreimer-Birnbaum M. Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin Hematol. 1989;26(2):157–173
  135. Furukawa K, Okunaka T, Tsuchida T, Kawate N, Konaka C, Kato H. A Phase I clinical study of photodynamic therapy of early stage lung carcinoma using ME2906 and a diode laser system. Porphyrins. 1998;7:199–206
  136. Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Clin Cancer Res. 1998;4(11):2741–2746
  137. Chan AL, Juarez M, Allen R, Volz W, Albertson T. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed. 2005;21(2):72–78
  138. Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003;42(1):103–111
  139. Usuda J, Tsutsui H, Honda H, Ichinose S, Ishizumi T, Hirata T, et al. Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy. Lung Cancer. 2007;58(3):317–323
  140. Yoshida T, Tokashiki R, Ito H, Shimizu A, Nakamura K, Hiramatsu H, et al. Therapeutic effects of a new photosensitizer for photodynamic therapy of early head and neck cancer in relation to tissue concentration. Auris Nasus Larynx. 2008;35(4):545–551
  141. Lustig RA, Vogl TJ, Fromm D, Cuenca R, Alex Hsi R, D’Cruz AK, et al. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003;98(8):1767–1771
  142. Chen J, Keltner L, Christophersen J, Zheng F, Krouse M, Singhal A, et al. New technology for deep light distribution in tissue for phototherapy. Cancer J. 2002;8(2):154–163
  143. Kujundzic M, Vogl TJ, Stimac D, Rustemovic N, Hsi RA, Roh M, et al. A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer. J Surg Oncol. 2007;96(6):518–524
  144. Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs. 2008;2008:276109
  145. Grekin R, Razun N, Trommer R, Dorion D, Snyder A. Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT): Results of a phase I/II clinical study conduced at UCSF for the treatment of AIDS-associted cutaneous Kaposi's sarcomas. In: International Conference on AIDS. 1996;
  146. Mang TS, Allison R, Hewson G, Snider W, Moskowitz R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am. 1998;4(6):378–384
  147. Kaplan MJ, Somers RG, Greenberg RH, Ackler J. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol. 1998;67(2):121–125
  148. Razum N, Snyder A, Doiron D. SnET2: clinical update. Proc Soc Photo-Opt Instrum Eng. 1996;2675:43–46
  149. Grin MC, Capital Em Cyrillicironov CA, Shtil AC. Bacteriochlorophyll a, and its derivatives: chemistry and perspectives for cancer therapy. Anticancer Agents Med Chem. 2008;8(6):683–697
  150. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol. 2009;6(1):18–30
  151. Weersink RA, Forbes J, Bisland S, Trachtenberg J, Elhilali M, Brun PH, et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol. 2005;81(1):106–113
  152. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008;102(5):556–562
  153. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol. 2007;178(5):1974–1979discussion 1979
  154. Haider MA, Davidson SR, Kale AV, Weersink RA, Evans AJ, Toi A, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology. 2007;244(1):196–204
  155. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol. 2000;59(7):733–739
  156. Sessler JL, Hemmi G, Mody TD, Murai T, Burrell A, Young SW. Texaphyrins:synthesis and applications. Acc Chem Res. 1994;27:43–50
  157. Mody TD, Sessler JL. Texaphyrins: a new approach to drug development. J Porphyrins Phthalocyan. 2001;5(2):134–142
  158. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol. 1996;63(6):892–897
  159. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19(7):2074–2083
  160. Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 2000;102(19):2322–2324
  161. Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation. 2003;108(11):1310–1315
  162. Renschler MF, Yuen AR, Panella TJ. Photodynamic therapy trials with lutetium texaphyrin. Photochem Photobiol. 1997;65:475
  163. Renschler MF, Yuen AR, Panella TJ, et al. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer. Proc Soc Photo-Opt Instrum Eng. 1998;3247:35–39
  164. Dimofte A, Zhu TC, Hahn SM, Lustig RA. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med. 2002;31(5):305–312
  165. Verigos K, Stripp DC, Mick R, Zhu TC, Whittington R, Smith D, et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol. 2006;25(1–2):373–388
  166. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol. 2006;175(4):1201–1207
  167. Patel H, Mick R, Finlay J, Zhu TC, Rickter E, Cengel KA, et al. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008;14(15):4869–4876
  168. Bonnett R, White RD, Winfield UJ, Berenbaum MC. Hydroporphyrins of the meso-tetrahydroxyphenyl porphyrin series as tumors photosensitizers. Biochem J. 1989;261:277–280
  169. Ronn AM, Nouri M, Lofgren LA, Steinberg BM, Westerborn A, Windhal T, et al. Human tissue levels and plasma pharmacokinetics of Temoporfin (Foscan®, mTHPC). Lasers Med Sci. 1996;11:267–272
  170. Mitra S, Foster TH. Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin. Photochem Photobiol. 2005;81(4):849–859
  171. Copper MP, Tan IB, Oppelaar H, Ruevekamp MC, Stewart FA. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003;129(7):709–711
  172. Dilkes MG, Benjamin E, Ovaisi S, Banerjee AS. Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol. 2003;117(9):713–717
  173. Fan KF, Hopper C, Speight PM, Buonaccorsi GA, Bown SG. Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int J Cancer. 1997;73(1):25–32
  174. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer. 2004;111(1):138–146
  175. Kubler AC, de Carpentier J, Hopper C, Leonard AG, Putnam G. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg. 2001;30(6):504–509
  176. D’Cruz AK, Robinson MH, Biel MA. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck. 2004;26(3):232–240
  177. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Fekete F. Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer. Bull Acad Natl Med. 2000;184(8):1731–1744discussion 1744-7
  178. Grosjean P, Savary JF, Mizeret J, Wagnieres G, Woodtli A, Theumann JF, et al. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. J Clin Laser Med Surg. 1996;14(5):281–287
  179. Friedberg JS, Mick R, Stevenson J, Metz J, Zhu T, Buyske J, et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003;75(3):952–959
  180. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest. 2001;120(4):1167–1174
  181. Ris HB, Altermatt HJ, Nachbur B, Stewart CM, Wang Q, Lim CK, et al. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med. 1996;18(1):39–45
  182. Savary JF, Monnier P, Fontolliet C, Mizeret J, Wagnieres G, Braichotte D, et al. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch Otolaryngol Head Neck Surg. 1997;123(2):162–168
  183. Ell C, Gossner L, May A, Schneider HT, Hahn EG, Stolte M, et al. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut. 1998;43(3):345–349
  184. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50(4):549–557
  185. Milkvy P, Messmann H, Macrobert AJ, et al. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Br J Cancer. 1997;76:713–718
  186. Baas P, Saarnak AE, Oppelaar H, Neering H, Stewart FA. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol. 2001;145(1):75–78
  187. Wyss P, Schwarz V, Dobler-Girdziunaite D, Hornung R, Walt H, Degen A, et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int J Cancer. 2001;93(5):720–724
  188. Nathan TR, Whitelaw DE, Chang SC, Lees WR, Ripley PM, Payne H, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol. 2002;168(4 Pt 1):1427–1432
  189. Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med. 2006;38(5):356–363
  190. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol. 2002;42(5):547–557
  191. Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina. 2002;22(6):691–697
  192. Leung J. Photosensitizers in photodynamic therapy. Semin Oncol. 1994;21:4–10
  193. Richter AM, Kelly B, Chow J, Liu DJ, Towers GH, Dolphin D, et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst. 1987;79(6):1327–1332
  194. Gragoudas E, Schmidt-Erfurth U, Sickenkey M. Results and preliminary dosimetry of photodynamic therapy for choroidal neovascularization in age-related macular degeneration in a phase I/II study. Assoc Res Vision Opthamol. 1997;38:73
  195. Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol. 2009;87(2):118–132
  196. Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study. Ophthalmic Surg Lasers Imaging. 2009;40(3):277–284
  197. Eskelin S, Tommila P, Palosaari T, Kivela T. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol. 2008;86(7):794–799
  198. Young LH, Howard MA, Hu LK, Kim RY, Gragoudas ES. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol. 1996;114(2):186–192
  199. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol. 2003;135(6):898–899
  200. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin Oncol. 1994;21(6 Suppl 15):11–14
  201. Burch S, London C, Seguin B, Rodriguez C, Wilson BC, Bisland SK. Treatment of canine osseous tumors with photodynamic therapy: a pilot study. Clin Orthop Relat Res. 2009;467(4):1028–1034
  202. Allison RR. PDT frontiers. Photodiagnosis Photodyn Ther. 2009;6(2):135–136
  203. Josefsen LB, Boyle RW. Photodynamic therapy: novel third-generation photosensitizers one step closer?. Br J Pharmacol. 2008;154(1):1–3
  204. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008;26(11):612–621
  205. Chatterjee DK, Yong Z. Upconverting nanoparticles as nanotransducers for photodynamic therapy in cancer cells. Nanomed. 2008;3(1):73–82
  206. Stefflova K, Chen J, Zheng G. Using molecular beacons for cancer imaging and treatment. Front Biosci. 2007;12:4709–4721

PII: S1572-1000(10)00027-X

doi: 10.1016/j.pdpdt.2010.02.001

Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 2 , Pages 61-75 , June 2010

Article Tools